I purchased KYMR shares because of the recent surge in stock price driven by Sanofi's expansion of Phase 2 trials for KT-474 and the successful pricin...
Read
More
I purchased KYMR shares because of the recent surge in stock price driven by Sanofi's expansion of Phase 2 trials for KT-474 and the successful pricing of Kymera’s $225 million public offering, which will accelerate the development of their promising pipeline.